Company Filing History:
Years Active: 1995-2005
Title: Brian Alexander Mc Kittrick: Innovator in Hepatitis C Research
Introduction
Brian Alexander Mc Kittrick, located in Bloomfield, NJ, is an accomplished inventor known for his contributions to medical research, particularly in the fight against hepatitis C virus (HCV). With two patents to his name, Mc Kittrick's work continues to address significant challenges in the pharmaceutical industry.
Latest Patents
Among his notable patents, Mc Kittrick has developed "Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties." This invention introduces novel macrocyclic compounds that demonstrate inhibitory activity against the HCV protease. Furthermore, it includes methods for preparing these compounds and pharmaceutical compositions that can be utilized to treat disorders associated with the HCV protease.
Another patent he holds is related to "Polycyclic guanine derivatives," which further showcases his innovative approach to developing pharmaceutical solutions. These patents highlight Mc Kittrick's commitment to advancing medical research and drug discovery.
Career Highlights
Mc Kittrick's career is marked by his significant work at Schering Corporation, where he has been instrumental in pioneering research and development initiatives. His expertise and innovative mindset have enabled the company to explore new therapeutic avenues, specifically related to hepatitis C treatments.
Collaborations
Throughout his career, Brian has collaborated with esteemed colleagues, including Bernard R. Neustadt and Neil A. Lindo. These collaborative efforts have driven the advancement of their projects and contributed to the growth of their respective fields within biomedical science.
Conclusion
Brian Alexander Mc Kittrick stands out as a notable inventor in the realm of hepatitis C research. His patented innovations not only reflect his dedication to tackling significant health issues but also underscore the collaborative spirit that accompanies scientific advancement. As he continues his work at Schering Corporation, the potential for further breakthroughs remains promising.